Treatment response to first-line therapy
| Response* . | CHOP-based regimens (n = 10) . | Hyper-CVAD (n = 11) . | SL-401 (n = 12) . | Others (n = 9) . | Total (N = 42) . |
|---|---|---|---|---|---|
| CR | 5 (50) | 10 (91) | 6 (50) | 2 (22) | 23 (55) |
| CRc | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| PR | 4 (40) | 1 (9) | 3 (25) | 5 (56) | 13 (31) |
| SD | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| PD | 1 (10) | 0 (0) | 3 (25) | 2 (22) | 6 (14) |
| Response* . | CHOP-based regimens (n = 10) . | Hyper-CVAD (n = 11) . | SL-401 (n = 12) . | Others (n = 9) . | Total (N = 42) . |
|---|---|---|---|---|---|
| CR | 5 (50) | 10 (91) | 6 (50) | 2 (22) | 23 (55) |
| CRc | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| PR | 4 (40) | 1 (9) | 3 (25) | 5 (56) | 13 (31) |
| SD | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| PD | 1 (10) | 0 (0) | 3 (25) | 2 (22) | 6 (14) |
Other treatments include radiation, steroid, methotrexate, thalidomide, and CLAG-M. Data represent n (%).
CR, complete response; CRc, complete response with minimal residual skin abnormality; SD, stable disease.
Treatment response was assessed according to criteria proposed by Pemmaraju et al.16